pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2020-30-4-473-484pulmo-2154Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYНовые перспективы ингаляционной терапии бронхиальной астмыThe new prospects of the inhalation therapy for bronchial asthmahttps://orcid.org/0000-0002-5999-2150АвдеевС. Н.AvdeevS. N.

Авдеев Сергей Николаевич – доктор медицинских наук, профессор, член-корр. Российской академии наук, заведующий кафедрой пульмонологии Федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), руководитель клинического отдела Федерального государственного бюджетного учреждения «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства

119991, Москва, ул. Трубецкая, 8, стр. 2, 

115682, Москва, Ореховый бульвар, 28

Sergey N. Avdeev, Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Head of Clinical Division, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia

ul. Trubetskaya 8, build. 2, Moscow, 119991, 

Orekhovyy bul'var 28, Moscow, 115682

serg_avdeev@list.ruhttps://orcid.org/0000-0002-4044-674XАйсановЗ. Р.AisanovZ. R.

Айсанов Заурбек Рамазанович – доктор медицинских наук, профессор кафедры пульмонологии

117997, Москва, ул. Островитянова, 1

Zaurbek R. Aisanov, Doctor of Medicine, Professor, Department of Pulmonology

ul. Ostrovityanova 1, Moscow, 117997

aisanov@mail.ruФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет); Федеральное государственное автономное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентстваРоссияI.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia; Federal Pulmonology Research Institute, Federal Medical and Biological Agency of RussiaRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Министерства здравоохранения Российской ФедерацииРоссияN.I.Pirogov Federal Russian National Research Medical University, Healthcare Ministry of RussiaRussian Federation202017102020304473484Copyright © Авдеев С.Н., Айсанов З.Р., 20202020Авдеев С.Н., Айсанов З.Р.Avdeev S.N., Aisanov Z.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2154

На основании новейших данных международной литературы в статье рассматриваются возможности применения фиксированных комбинаций длительно действующих β2-агонистов, длительно действующих антихолинергических препаратов и ингаляционных глюко - кортикостероидов в достижении контроля над бронхиальной астмой (БА). По данным анализа результатов недавно завершенных рандомизированных клинических исследований IRIDIUM и ARGON представлены клинические преимущества применения фиксированной комбинации индакатерола, гликопиррония и мометазона фуроата c однократным режимом дозирования в терапии БА.

Based on the latest new international literature data, the article considers the possibilities of fixed combinations of long-acting β2-agonist, long-acting muscarinic antagonist and inhaled corticosteroids in achieving the control of bronchial asthma (BA). Clinical advantages for a fixed combination of indacaterol, glycopyrronium and mometasone furoate one dosing regimen in the therapy of BA are presented based on the results of recently completed randomized clinical trials IRIDIUM and ARGON.

бронхиальная астмаконтроль над бронхиальной астмойобострениядлительно действующие бронходилататорыингаляционные глюкокортикостероидыbronchial asthmacontrol of bronchial asthmaexacerbationslong acting bronchodilatorsinhaled corticosteroidsReferencesGlobal Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2020. Available at: https://ginasthma.org [Accessed: August 07, 2020].Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2020. Available at: https://ginasthma.org [Accessed: August 07, 2020].Beasley R., Harper J., Bird G. et al. Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am. J. Respir. Crit. Care Med. 2019; 199 (12): 1471–1477. DOI: 10.1164/rccm.201810-1868CI.Beasley R., Harper J., Bird G. et al. Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am. J. Respir. Crit. Care Med. 2019; 199 (12): 1471–1477. DOI: 10.1164/rccm.201810-1868CI.Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844. DOI: 10.1164/rccm.200401-033OC.Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844. DOI: 10.1164/rccm.200401-033OC.Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim. Care Respir. Med. 2014; 24: 24009. DOI: 10.1038/npjpcrm.2014.9.Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim. Care Respir. Med. 2014; 24: 24009. DOI: 10.1038/npjpcrm.2014.9.Hansen R., Seifeldin R., Noe L. Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant. Proc. 2007; 39 (5): 1287–1300. DOI: 10.1016/j.transproceed.2007.02.074.Hansen R., Seifeldin R., Noe L. Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant. Proc. 2007; 39 (5): 1287–1300. DOI: 10.1016/j.transproceed.2007.02.074.Fink J.B., Rublin B.K. Problem with inhaler use: a call for improved clinician and patient education. Respir. Care. 2005; 50 (10): 1360–1374.Fink J.B., Rublin B.K. Problem with inhaler use: a call for improved clinician and patient education. Respir. Care. 2005; 50 (10): 1360–1374.Kew K.M., Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst. Rev. 2016; (1): CD011721. DOI: 10.1002/14651858.CD011721.pub2.Kew K.M., Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst. Rev. 2016; (1): CD011721. DOI: 10.1002/14651858.CD011721.pub2.Barnes P.J. Distribution of receptor targets in the lung. Proc. Am. Thorac. Soc. 2004; 1 (4): 345–351. DOI: 10.1513/pats.200409-045MS.Barnes P.J. Distribution of receptor targets in the lung. Proc. Am. Thorac. Soc. 2004; 1 (4): 345–351. DOI: 10.1513/pats.200409-045MS.Gwilt C.R., Donnelly L.E., Rogers D.F. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol. Ther. 2007; 115 (2): 208–222. DOI: 10.1016/j.pharmthera.2007.05.007.Gwilt C.R., Donnelly L.E., Rogers D.F. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol. Ther. 2007; 115 (2): 208–222. DOI: 10.1016/j.pharmthera.2007.05.007.Price D., Fromer L., Kaplan A. et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim. Care Respir. Med. 2014; 24: 14023. DOI: 10.1038/npjpcrm.2014.23.Price D., Fromer L., Kaplan A. et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim. Care Respir. Med. 2014; 24: 14023. DOI: 10.1038/npjpcrm.2014.23.Grainge C.L., Lau L.C.K., Ward J.A. et al. Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 2011; 364 (21): 2006–2015. DOI: 10.1056/NEJMoa1014350.Grainge C.L., Lau L.C.K., Ward J.A. et al. Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 2011; 364 (21): 2006–2015. DOI: 10.1056/NEJMoa1014350.Kerstjens H.A.M., Maspero J., Chapman K.R. et al. Oncedaily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. [Published online: July 9, 2020]. Lancet Respir. Med. 2020; S2213-2600(20)30190-9. DOI: 10.1016/S2213-2600(20)30190-9.Kerstjens H.A.M., Maspero J., Chapman K.R. et al. Oncedaily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. [Published online: July 9, 2020]. Lancet Respir. Med. 2020; S2213-2600(20)30190-9. DOI: 10.1016/S2213-2600(20)30190-9.Gessner C., Kornmann O., Maspero J. et al. Fixed-dose combination of indacaterol/glycopyrronium/ mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respir. Med. 2020; 170: 106021. DOI: 10.1016/j.rmed.2020.106021.Gessner C., Kornmann O., Maspero J. et al. Fixed-dose combination of indacaterol/glycopyrronium/ mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respir. Med. 2020; 170: 106021. DOI: 10.1016/j.rmed.2020.106021.Fausnight T., Craig T. Mometasone furoate dry powder inhaler for the treatment of asthma. Exp. Opin. Pharma - cother. 2011; 12 (17): 2707–2712. DOI: 10.1517/14656566.2011.630390.Fausnight T., Craig T. Mometasone furoate dry powder inhaler for the treatment of asthma. Exp. Opin. Pharma - cother. 2011; 12 (17): 2707–2712. DOI: 10.1517/14656566.2011.630390.Juniper E.F., Bousquet J., Abetz L., Bateman E.D. Identifying “well-controlled” and “not well-controlled” asthma using the Asthma Control Questionnaire. Respir. Med. 2006; 100 (4): 616–621. DOI: 10.1016/j.rmed.2005.08.012.Juniper E.F., Bousquet J., Abetz L., Bateman E.D. Identifying “well-controlled” and “not well-controlled” asthma using the Asthma Control Questionnaire. Respir. Med. 2006; 100 (4): 616–621. DOI: 10.1016/j.rmed.2005.08.012.Papi A., Humbert M., Kostikas K. et al. Medium-dose indacaterol/glycopyrronium/mometasone furoate fixed-dose combination improves lung function compared with highdose indacaterol/mometasone furoate and salmeterol/fluticasone and reduces exacerbation rates versus high-dose salmeterol/fluticasone in moderate-to-severe asthma: the IRIDIUM study. Am. J. Respir. Crit. Care Med. 2020; 201: A3008. DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3008.Papi A., Humbert M., Kostikas K. et al. Medium-dose indacaterol/glycopyrronium/mometasone furoate fixed-dose combination improves lung function compared with highdose indacaterol/mometasone furoate and salmeterol/fluticasone and reduces exacerbation rates versus high-dose salmeterol/fluticasone in moderate-to-severe asthma: the IRIDIUM study. Am. J. Respir. Crit. Care Med. 2020; 201: A3008. DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3008.Price D., Robertson A., Bullen K. et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm. Med. 2010; 10: 1. DOI: 10.1186/1471-2466-10-1.Price D., Robertson A., Bullen K. et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm. Med. 2010; 10: 1. DOI: 10.1186/1471-2466-10-1.Virchow J.C., Kuna P., Paggiaro P. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRI-MARAN and TRIGGER): two double-blind, parallelgroup, randomised, controlled phase 3 trials. Lancet. 2019; 394 (10210): 1737–1749. DOI: 10.1016/S0140-6736(19)32215-9.Virchow J.C., Kuna P., Paggiaro P. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRI-MARAN and TRIGGER): two double-blind, parallelgroup, randomised, controlled phase 3 trials. Lancet. 2019; 394 (10210): 1737–1749. DOI: 10.1016/S0140-6736(19)32215-9.Pavord I., Peachey G., Kerstjens H. et al. Once-daily, sing - le-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study. J. Allergy Clin. Immunol. 2020; 145 (2, Suppl.): AB241. DOI: 10.1016/j.jaci.2019.12.141.Pavord I., Peachey G., Kerstjens H. et al. Once-daily, sing - le-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study. J. Allergy Clin. Immunol. 2020; 145 (2, Suppl.): AB241. DOI: 10.1016/j.jaci.2019.12.141.Juniper E.F., Buist A.C., Cox F.V. et al. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999; 115 (5): 1265–1270. DOI: 10.1378/chest.115.5.1265.Juniper E.F., Buist A.C., Cox F.V. et al. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999; 115 (5): 1265–1270. DOI: 10.1378/chest.115.5.1265.Kornmann O., Dahl R., Centanni S. et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebocontrolled comparison. Eur. Respir. J. 2011; 37 (2): 273–279. DOI: 10.1183/09031936.00045810.Kornmann O., Dahl R., Centanni S. et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebocontrolled comparison. Eur. Respir. J. 2011; 37 (2): 273–279. DOI: 10.1183/09031936.00045810.Kerwin E., Hebert J., Gallagher N. et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 2012; 40 (5): 1106–1114. DOI: 10.1183/09031936.00040712.Kerwin E., Hebert J., Gallagher N. et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 2012; 40 (5): 1106–1114. DOI: 10.1183/09031936.00040712.Donohue J.F., Betts K.A., Du E. et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 367–381. DOI: 10.2147/COPD.S119908.Donohue J.F., Betts K.A., Du E. et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 367–381. DOI: 10.2147/COPD.S119908.Yang D., Wang J., Bunjhoo H. et al. Comparison of the efficacy and safety of mometasone furoate to other inhaled steroids for asthma: a meta-analysis. Asian. Pac. J. Allergy Immunol. 2012; 31 (1): 26–35.Yang D., Wang J., Bunjhoo H. et al. Comparison of the efficacy and safety of mometasone furoate to other inhaled steroids for asthma: a meta-analysis. Asian. Pac. J. Allergy Immunol. 2012; 31 (1): 26–35.Derendorf H., Nave R., Drollmann A. et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28 (5): 1042– 1050. DOI: 10.1183/09031936.00074905.Derendorf H., Nave R., Drollmann A. et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28 (5): 1042– 1050. DOI: 10.1183/09031936.00074905.Valotis A., Hogger P., Neukam K., Elert O. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J. Pharm. Sci. 2004; 93 (5): 1337–1350. DOI: 10.1002/jps.20049Valotis A., Hogger P., Neukam K., Elert O. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J. Pharm. Sci. 2004; 93 (5): 1337–1350. DOI: 10.1002/jps.20049

The authors declare that there are no conflicts of interest present.